Cyclopeptide Utilizing Patents (Class 514/21.1)
  • Patent number: 10100084
    Abstract: Template-fixed ?-hairpin peptidomimetics of the general formulae wherein Z is a chain of 11 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 16, 2018
    Assignees: POLYPHOR LTD., UNIVERSITAT ZURICH
    Inventors: Steven J. Demarco, Kerstin Moehle, Heiko Henze, Odile Sellier, Francoise Jung, Frank Gombert, Daniel Obrecht, Christian Ludin
  • Patent number: 10035824
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 31, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Patent number: 9700592
    Abstract: Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: July 11, 2017
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Patent number: 9675661
    Abstract: Peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production are described.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 13, 2017
    Assignee: AILERON THERAPEUTICS, INC.
    Inventor: Huw M. Nash
  • Patent number: 9220771
    Abstract: The invention relates to the use of the Peptide of the formula Cyclo-(Arg-Gly-Asp-DPhe-NMe-Val) and/or the pharmaceutically acceptable derivatives, solvates and/or salts thereof, for the manufacture of a medicament for the treatment of breast cancer and/or bone metastases in humans, wherein the medicament is optionally to be used in combination with one or more cancer cotherapeutic agents, preferably selected from a) hormone modulating agents, b) osteoclast activity modulating agents, c) cancer chemotherapeutic agents, and/or d) radiotherapy, alone, concurrently or not in the dosage regime of the present invention.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: December 29, 2015
    Assignee: MERCK PATENT GMBH
    Inventors: Anne Kerber, Tobias Baeuerle
  • Patent number: 9175056
    Abstract: Peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production are described.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: November 3, 2015
    Assignee: Alleron Therapeutics, Inc.
    Inventor: Huw M. Nash
  • Patent number: 9056076
    Abstract: The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: June 16, 2015
    Assignee: Potentia Pharmaceuticals, Inc.
    Inventors: Pascal Deschatelets, Paul Olson, Cedric Francois
  • Publication number: 20150148290
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 28, 2015
    Inventors: Eric Marsault, Carl St-Louis
  • Publication number: 20150141349
    Abstract: This invention relates to methods and compositions for treating carcinoid syndrome and other adverse symptoms associated with tumor-producing neuroendocrine tumors, said methods comprising administering a therapeutically effective amount of a vascular disrupting agent, or a pharmaceutically acceptable salt thereof, to a subject having a hormone producing neuroendocrine tumor. In preferred implementations, the vascular disrupting agent is combretastatin A-4 phosphate, combretastatin A-1 diphosphate, or a pharmaceutical acceptable salt thereof.
    Type: Application
    Filed: June 21, 2013
    Publication date: May 21, 2015
    Applicant: Angiogene Pharmaceuticals Ltd.
    Inventors: Peter David Davis, David J. Chaplin
  • Publication number: 20150132238
    Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Inventors: Adelya K. Leshchiner, Nancy E. Larsen, Edward G. Parent
  • Publication number: 20150132237
    Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Inventors: Adelya K. Leshchiner, Nancy E. Larsen, Edward G. Parent
  • Publication number: 20150132375
    Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 14, 2015
    Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
  • Patent number: 9029332
    Abstract: Cross-linked proteins and peptides, and methods of making and uses of such cross-linked proteins and peptides. The cross-linked proteins and peptides have rigid, distance-matching bismethylene aryl cross-linking moieties. Compositions comprising the cross-linked proteins and peptides can be used as pharmaceutical delivery formulations. The cross-linked proteins and peptides can have improved properties, such as cell permeability, as compared to the parent protein or peptide.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 12, 2015
    Assignee: The Research Foundation for The State University of New York
    Inventors: Qing Lin, Avinash Muppidi
  • Publication number: 20150126450
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: May 7, 2015
    Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian
  • Publication number: 20150126432
    Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 7, 2015
    Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
  • Publication number: 20150126451
    Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventors: William D. Carlson, Peter C. Keck, Michael Sworin, Dattatreyamurty Bosukonda, Kellie Watson, Philippe Bey, Romesh Subramanian
  • Patent number: 9023258
    Abstract: A method and formulation for preparing spray dried vancomycin. In various embodiment, the formulation includes vancomycin HCl (10-20%) and one or more of the following PEG (0-5%), mannitol (0-5%), ethanol (0-10%), and a citrate buffer. Spray dried vancomycin has favorable reconstitution times and water content.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: May 5, 2015
    Assignee: Hospira, Inc.
    Inventors: Cynthia Fragale, Daniel Brueck
  • Patent number: 9023988
    Abstract: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production. Macrocycles of the invention include triazole moieties that crosslink amino acid side chains. The cross links can stabilize a secondary structure of a peptidomimetic macrocycle, such as an ?-helix.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 5, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventor: Huw M. Nash
  • Patent number: 9018172
    Abstract: Disclosed are compounds and methods relating to a chemical transformation for the conjugation of unprotected peptide biomolecules via a SNAr process between highly fluorinated aryl moieties and thiols (“fluoroaryl-thiol-click”).
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: April 28, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Bradley L. Pentelute, Alexander M. Spokoyny, Yekui Zou, Chi Zhang
  • Publication number: 20150105332
    Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
    Type: Application
    Filed: May 24, 2013
    Publication date: April 16, 2015
    Applicant: CAMURUS AB
    Inventors: Catalin Nistor, Markus Johnsson, Fredrik Tiberg
  • Publication number: 20150105333
    Abstract: Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-?B activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-?B activity without a second delayed increase in NF-?B activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated Massilia bacterium or population thereof capable of producing a HIV-1 reactivating factor (HRF). Also provided are methods of culturing the Massilia bacteria. Further provided are methods of reactivating a latent Human Immunodeficiency Virus-1 (HIV-1) infection in a subject comprising administering to the subject a HIV-1 reactivating factor produced by Massilia bacteria, optionally with a priming agent.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 16, 2015
    Inventors: Olaf Kutsch, Michael Niederweis, Frank Wolschendorf, Alexandra Duverger, Frederic Wagner
  • Publication number: 20150105335
    Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Richard Franklin
  • Publication number: 20150105328
    Abstract: The invention concerns peptoid-peptide hybrids that may act as protein interaction inhibitors (PPIIs). Another aspect of the invention concerns a method for treating a disorder (e.g., an oncologic disorder) in a human or animal subject, comprising administering an effective amount of a peptoid-peptide hybrid (a peptoid body) of the invention, or a composition comprising a peptoid-peptide hybrid, to the subject in need thereof. Another aspect of the subject invention concerns a method for killing or inhibiting the growth of cells (e.g., cancer cells or malaria-infected cells), comprising contacting a cancer cell in vitro or in vivo with an effective amount of a peptoid-peptide hybrid, or a composition comprising the peptoid-peptide hybrid. Another aspect of the invention concerns a method for producing a peptoid-peptide hybrid.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: MARK MCLAUGHLIN, PRIYESH JAIN
  • Publication number: 20150105331
    Abstract: A high purity cyclopeptide crystal has a structure shown by Formula I. R represents H or a cation forming a pharmaceutically acceptable salt. Also disclosed are a preparation method and a use of the high-purity cyclopeptide crystal.
    Type: Application
    Filed: March 29, 2013
    Publication date: April 16, 2015
    Inventors: Shidong Liu, Zhaoli Zhang, Xiusheng Wang, Xiao Zhang, Zhijun Tang, Xiaoming Ji
  • Patent number: 9006392
    Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: April 14, 2015
    Assignee: Novacta Biosystems Limited
    Inventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
  • Publication number: 20150094265
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: December 1, 2014
    Publication date: April 2, 2015
    Inventors: ANGELIKA FRETZEN, HONG ZHAO, MARCO KESSLER
  • Publication number: 20150094272
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: August 17, 2012
    Publication date: April 2, 2015
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Marco Kessler, Angelika Fretzen, Hong Zhao, Robert Solinga, Vladimir Volchenok
  • Patent number: 8993581
    Abstract: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: March 31, 2015
    Assignee: Trustees of Boston University
    Inventors: Susan Perrine, Douglas Faller
  • Patent number: 8992940
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: March 31, 2015
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Publication number: 20150087597
    Abstract: Described herein are fragments of fibronectin and vitronectin and variants thereof that have certain activities, including growth factor-binding activity. Also described are fragments of growth factors that bind to fibronectin and inhibit binding of full-length growth factors to fibronectin. Compositions containing such fragments are useful in cosmetic treatments (e.g., the treatment of wrinkles or UV photodamage of skin), and the treatment of wounds and cancer.
    Type: Application
    Filed: May 1, 2014
    Publication date: March 26, 2015
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventor: Richard A. Clark
  • Publication number: 20150080319
    Abstract: A method is provided for inhibiting TACE activity in a human subject, through the administration of a ?-defensin, analog, or derivative. Such a ?-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally. The ?-defensin, analog, or derivative can be selected to additionally inhibit ADAM-10 activity.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 19, 2015
    Inventors: Michael E. Selsted, Dat Q. Tran
  • Publication number: 20150078999
    Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
    Type: Application
    Filed: June 20, 2014
    Publication date: March 19, 2015
    Inventors: James R. Heath, Rosemary Dyane Rohde, Arundhati Nag, Samir Das, Aiko Umeda
  • Publication number: 20150080312
    Abstract: This invention relates to an isolated, compound of Formula (1) or derivatives or pharmaceutically acceptable salts thereof. The invention also includes all isomeric and tautomeric forms of the compound of Formula (1) or the derivatives thereof. The present invention further relates to processes for the production of the compound of Formula (1) by fermentation of the fungal strain of Actinomycetes (PM0895172/MTCC 684), pharmaceutical compositions comprising the compound of Formula (1) as the active ingredient; and use of the compounds or composition containing them in the treatment of cancer.
    Type: Application
    Filed: May 6, 2013
    Publication date: March 19, 2015
    Applicant: PIRAMAL ENTERPRISES LIMITED
    Inventors: Prabhu Dutt Mishra, Sreekumar Sankaranarayanan Eyyammadichiyl, Saji David George, Shailendra Sonawane, Narayan Subhash Chakor, Abhijit Roychowdhury, Rajiv Sharma
  • Patent number: 8981048
    Abstract: Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: March 17, 2015
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
  • Patent number: 8980827
    Abstract: The present invention provides a medicinal composition containing micafungin or a pharmaceutically acceptable salt thereof and trehalose as a stabilizing agent.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: March 17, 2015
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Yunhai Hong, Ying Xue, Xiaoming Ji
  • Publication number: 20150071918
    Abstract: The invention relates to novel cyclic compounds (cyclic peptides), linkers useful as beta-turn promoters in cyclic peptides, and methods for treatment of malignant cells in vitro or in vivo using one or more linear and cyclic peptides. The peptides can act as integrin interaction inhibitors and may be used in the treatment of cancers as monotherapies or in combination with other anti-cancer agents, such as proteasome inhibitors, inhibitors of autophagy, alkylating agents, MEK inhibitors, FAK/PYK2 inhibitors, and EGFR inhibitors. The invention further concerns a method of predicting the binding of a cyclic or linear HYD1 peptide to a cancer cell by assessing overexpression of biomarkers such as CD44, VLA-4 integrin, basigin, CD138 (syndecan 1), NCAM, ICAM1, ICAM3, and CD59.
    Type: Application
    Filed: May 9, 2013
    Publication date: March 12, 2015
    Inventors: Mark McLaughlin, Lori Hazlehurst, Priyesh Jain, Michael F. Emmons, Anthony W. Gebhard, Rajesh R. Nair
  • Publication number: 20150072939
    Abstract: The present invention relates to the use of 5-HT2 receptor antagonists and in particular of 8-?-ergolines such as lisuride, terguride and the derivatives thereof as 5-HT2B and 5-HT2A receptor antagonists and antioxidants in preferably higher-dosed and preferably continuous use for the treatment, progression prophylaxis and general prophylaxis of organ fibroses and other pathological organ remodeling caused by mesenchymal proliferation
    Type: Application
    Filed: September 22, 2014
    Publication date: March 12, 2015
    Applicant: SINOXA PHARMA GMBH
    Inventors: Reinhard HOROWSKI, Heinz PALLA, Johannes TACK
  • Patent number: 8975368
    Abstract: Peptide nanotube polymers and methods of making such are disclosed. The peptide nanotube polymers are comprised of alternating monomers of the first peptide ring and monomers of the second peptide ring covalently bonded to one another via a linker, and can be functionalized. The described peptide nanotube polymers can enjoy the combined properties of healing and toughness, self-reporting, and tunability and actuation.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: March 10, 2015
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: John L. Kulp, III, Manoj K. Kolel-Veetil, Thomas D. Clark
  • Publication number: 20150065434
    Abstract: Provided herein are cyclic peptide inhibitors of lysine-specific demethylase 1. These cyclic peptides have the potential to treat cancer, diabetes, cardiovascular disease, and neurological disorders.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Patrick M. WOSTER, Isuru R. KUMARASINGHE
  • Patent number: 8969308
    Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: March 3, 2015
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
  • Patent number: 8969513
    Abstract: Disclosed are a caspofungin analog and applications thereof. The caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable salts thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of the compound.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: March 3, 2015
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
  • Patent number: 8969309
    Abstract: The present invention discloses a crystal of a peptide substance and the preparation method as well as the use thereof. Said crystal B possesses peaks at the following 2? angles in the X-ray diffraction pattern (XRPD): 3.2±0.2°, 5.4±0.2°, 6.2±0.2°, and 9.3±0.2°.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: March 3, 2015
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Shidong Liu, Zhaoli Zhang, Zhonghao Zhuo, Xiaoming Ji, Xiaoliang Gao
  • Patent number: 8969307
    Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 8969306
    Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Publication number: 20150057234
    Abstract: Disclosed is a hydrate of a compound as shown in Formula I. In formula I, R represents H or a cation capable of forming a pharmaceutically acceptable salt. The mass percentage of water in the hydrate is more than 8%. The hydrate has good stability. Moreover, disclosed are a preparation method and a use thereof.
    Type: Application
    Filed: March 29, 2013
    Publication date: February 26, 2015
    Inventors: Shidong Liu, Zhaoli Zhang, Xiusheng Wang, Xiao Zhang, Zhijun Tang, Xiaoming Ji
  • Publication number: 20150057235
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Application
    Filed: October 30, 2014
    Publication date: February 26, 2015
    Inventors: Kunwar SHAILUBHAI, Gary S. JACOB
  • Publication number: 20150056217
    Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
    Type: Application
    Filed: August 26, 2013
    Publication date: February 26, 2015
    Applicant: University of Pittsburgh - of the Commonwealth System of Highter Education
    Inventor: DAVID J. HACKAM
  • Patent number: 8962568
    Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: February 24, 2015
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
  • Patent number: 8962795
    Abstract: Factor H-binding peptides that binds to a region of factor H that does not impede the complement-inhibitory activity of factor H are disclosed. When immobilized onto the surface of a biomaterial, these peptides recruit factor H, resulting in a substantial inhibition of biomaterial-induced complement activation in a biological substance exposed to the biomaterial.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: February 24, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: John D. Lambris
  • Publication number: 20150050237
    Abstract: The present invention relates to the field of anti-mycobacterial therapeutics, in particular the treatment of tuberculosis, especially including pulmonary multidrug-resistant tuberculosis (MDR-TB), with applications in extensively drug-resistant tuberculosis (XDR-TB) and extremely drug-resistant tuberculosis (XXDR-TB), preferably in combination therapy.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 19, 2015
    Inventors: Vasu Nair, Maurice O. Okello, Machhindra G. Gund, Byung I. Seo, Pankajkumar R. Singh, Naveen K. Mangu